Overview

Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance

Status:
Completed

Trial end date:
2019-03-01

Target enrollment:
0

Participant gender:
All

Summary

This is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Henrik Gudbergsen

Treatments:

Liraglutide

Criteria

Inclusion Criteria:

- Same as parent trial (NCT02905864)

Exclusion Criteria:

- Same as parent trial (NCT02905864)